UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Brodalumab in psoriasis: evidence to date and clinical potential

Drugs in Context, 2019, Vol.8, p.212570-11

2019

Volltextzugriff (PDF)

Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics

Journal of investigative dermatology, 2023-08, Vol.143 (8), p.1470-1478.e1

2023

Volltextzugriff (PDF)

A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis

Journal of investigative dermatology, 2019-01, Vol.139 (1), p.100-107

2019

Volltextzugriff (PDF)

Genetic prediction of treatment response in psoriasis is still a work in progress

British journal of dermatology (1951), 2017-08, Vol.177 (2), p.344-345

2017

Volltextzugriff (PDF)

Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis

JAMA dermatology (Chicago, Ill.), 2024-01, Vol.160 (1), p.71

2024

Volltextzugriff (PDF)

The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study

British journal of dermatology (1951), 2023-03, Vol.188 (4), p.542-551

2023

Volltextzugriff (PDF)

Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2021-03, Vol.35 (2), p.187-199

2021

Volltextzugriff (PDF)

Research Techniques Made Simple: Bioinformatics for Genome-Scale Biology

Journal of investigative dermatology, 2017-09, Vol.137 (9), p.e163-e168

2017

Volltextzugriff (PDF)

Pharmacogenomics and the Resulting Impact on Psoriasis Therapies

Dermatologic clinics, 2015, Vol.33 (1), p.149-160

2015

Volltextzugriff (PDF)

Methotrexate Toxicity During Treatment of Chronic Plaque Psoriasis: A Case Report and Review of the Literature

Dermatology and therapy, 2014-12, Vol.4 (2), p.145-156

2014

Volltextzugriff (PDF)

DP04 Role of multidisciplinary team meetings in management of inflammatory skin conditions

British journal of dermatology (1951), 2023-06, Vol.188 (Supplement_4)

2023

Volltextzugriff (PDF)

Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis

The Journal of dermatological treatment, 2014-02, Vol.25 (1), p.61-62

2014

Volltextzugriff (PDF)

P38 Integrating proteomics and genomics to investigate the mechanisms of paradoxical eczema developing in patients with psoriasis treated with biologics: a UK multicentre, longitudinal, cohort study

British journal of dermatology (1951), 2023-06, Vol.188 (Supplement_4)

2023

Volltextzugriff (PDF)

P94 Bimekizumab early treatment response translated into cumulative benefits in health-related quality of life in patients with moderate-to-severe plaque psoriasis: results from 2 years of the BE RADIANT phase IIIb trial

British journal of dermatology (1951), 2023-06, Vol.188 (Supplement_4)

2023

Volltextzugriff (PDF)

O05 Single-cell transcriptomic signature of paradoxical eczema in patients with psoriasis treated with biologics

British journal of dermatology (1951), 2024-05, Vol.190 (6), p.e70-e70

2024

Volltextzugriff (PDF)

Paradoxical eczema in patients with psoriasis receiving biologics: a case series

Clinical and experimental dermatology, 2022-06, Vol.47 (6), p.1174-1178

2022

Volltextzugriff (PDF)

The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs

Rheumatology (Oxford, England), 2022-08, Vol.61 (9), p.e255-e266

2022

Volltextzugriff (PDF)

Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs

Rheumatology (Oxford, England), 2022-08, Vol.61 (9), p.3514-3520

2022

Volltextzugriff (PDF)

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Rheumatology (Oxford, England), 2021-04, Vol.60 (4), p.1588-1592

2021

Volltextzugriff (PDF)

Patients' Narratives

Current problems in dermatology, 2013, Vol.44, p.145-157

2013

Volltextzugriff (PDF)

Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis

Journal of Dermatological Treatment, 2014, Vol.25 (1), p.61-62

2014

Volltextzugriff (PDF)

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation

Journal of clinical oncology, 2014-05, Vol.32 (15), p.1547-1553

2014

Volltextzugriff (PDF)

Cardio-oncology and Cancer Rehabilitation: Is an Integrated Approach Possible?

Canadian journal of cardiology, 2023-11, Vol.39 (11S), p.S315-S322

2023

Volltextzugriff (PDF)

Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study

Circulation (New York, N.Y.), 2023-02, Vol.147 (7), p.532-545

2023

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(40)

Publikationsform

Sprache

Englisch
(59)

Erscheinungsjahr

n.n

Thema

Science & Technology
(42)
Life Sciences & Biomedicine
(41)
Humans
(32)
Adult
(14)
Female
(14)
Dermatology
(12)
Middle Aged
(12)
Psoriasis
(11)
Oncology
(10)
Aged
(9)
Cardiac & Cardiovascular Systems
(7)
Cardiovascular System & Cardiology
(7)
Male
(7)
Mutation
(6)
Breast Cancer
(5)
Psoriasis - Drug Therapy
(5)
Risk Factors
(5)
Biological Products - Therapeutic Use
(4)
Biomedical And Life Sciences
(4)
Brca2 Protein - Genetics
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Brodalumab in psoriasis: evidence to date and clinical potential

Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics

A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis

Genetic prediction of treatment response in psoriasis is still a work in progress

Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis

The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study

Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists

Research Techniques Made Simple: Bioinformatics for Genome-Scale Biology

Pharmacogenomics and the Resulting Impact on Psoriasis Therapies

Methotrexate Toxicity During Treatment of Chronic Plaque Psoriasis: A Case Report and Review of the Literature

DP04 Role of multidisciplinary team meetings in management of inflammatory skin conditions

Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis

P38 Integrating proteomics and genomics to investigate the mechanisms of paradoxical eczema developing in patients with psoriasis treated with biologics: a UK multicentre, longitudinal, cohort study

P94 Bimekizumab early treatment response translated into cumulative benefits in health-related quality of life in patients with moderate-to-severe plaque psoriasis: results from 2 years of the BE RADIANT phase IIIb trial

O05 Single-cell transcriptomic signature of paradoxical eczema in patients with psoriasis treated with biologics

Paradoxical eczema in patients with psoriasis receiving biologics: a case series

The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs

Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Patients' Narratives

The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope

Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation

Cardio-oncology and Cancer Rehabilitation: Is an Integrated Approach Possible?

Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study

Suchergebnisse filtern